"Our comprehensive cancer center blends world class expertise, continuity of care, and cutting edge technology. We provide the latest cancer treatments including chemotherapy, immunotherapy, and antibody therapy."

During the past decade, Gettysburg Cancer Center conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 18 clinical trials were completed, i.e. on average, 40.9% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 13 clinical trials were completed. i.e. 56.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gettysburg Cancer Center" #1 sponsor was "Incyte Corporation" with 3 trials, followed by "Celgene" with 2 trials sponsored, "Constellation Pharmaceuticals" with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored and "G1 Therapeutics, Inc." with 2 trials sponsored. Other sponsors include 41 different institutions and companies that sponsored additional 44 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gettysburg Cancer Center" #1 collaborator was "Hoosier Cancer Research Network" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "ARMO BioSciences" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "Bionomics Limited" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Gettysburg Cancer Center" are "Pancreatic Cancer" (6 trials), "Breast Cancer" (4 trials), "Non Small Cell Lung Cancer" (4 trials), "Non-small Cell Lung Cancer" (4 trials) and "Advanced or Metastatic Solid Tumors" (3 trials). Many other conditions were trialed in "Gettysburg Cancer Center" in a lesser frequency.

Most popular intervention types in "Gettysburg Cancer Center" are "Drug" (50 trials), "Other" (7 trials), "Biological" (4 trials), "Device" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Carboplatin" (5 trials), "Pembrolizumab" (4 trials), "Pemetrexed" (4 trials) and "Cisplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Gettysburg Cancer Center" are 49 trials for "All" genders, 5 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Gettysburg Cancer Center". undefined are not yet recruiting, 14 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Gettysburg Cancer Center, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Gettysburg Cancer Center, 15 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".